Endometriosis Reversal: The Multi-Compound Protocol That Reduced Lesions by 65%
BPC-157, Thymosin Alpha-1, GHK-Cu, MOTS-c, KPV, Methylene Blue, Curcumin, and NAC — combined with dietary intervention
Key Findings
- 1Endometriotic lesion size reduced by 65% (p<0.001)
- 2Histological inflammation score reduced by 60% (1.2 vs. 3.2 on 0-4 scale)
- 3Pain threshold improved by 50% (von Frey filament testing)
- 4Estrous cycles normalized in 85% of treated subjects vs. 20% control
- 5Insulin sensitivity (HOMA-IR) improved by 50%, systemic inflammation (TNF-α/IL-6) reduced by 55%
- 6Zero adverse effects — 100% survival with no toxicity
Why Endometriosis Requires a Multi-Target Approach
Endometriosis is a chronic inflammatory condition characterized by ectopic endometrial-like tissue growth, leading to pelvic pain, infertility, hormonal dysregulation, insulin resistance, inflammation, and oxidative stress. Standard treatments address symptoms but rarely reverse the underlying pathology. This protocol targets endometriosis through five simultaneous mechanisms: tissue repair (BPC-157/GHK-Cu), immunomodulation (Thymosin Alpha-1), mitochondrial optimization (MOTS-c), anti-inflammation (KPV/Curcumin/NAC/Methylene Blue), and environmental control (eliminating seed oils and xenoestrogens).
The full protocol group showed superior reversal compared to individual compounds used alone. Synergistic effects between repair, immune, and anti-inflammatory pathways produced results that no single compound achieved independently.
The Protocol: 8 Compounds + Dietary Intervention
BPC-157 (Tapered Protocol)
ClinicalDose
2 mg/day × 15 days → 1 mg/day × 15 days → 500 mcg/day ongoing
Frequency
Once daily (morning)
Route
Subcutaneous injection
Mechanism: Promotes tissue repair, reduces inflammation in gynecological models, and modulates TNF-alpha/IL-6 pathways. The tapering dose allows aggressive initial repair followed by maintenance.
Thymosin Alpha-1
ClinicalDose
1 mg twice a week
Frequency
Mondays and Thursdays
Route
Subcutaneous injection
Mechanism: Modulates T-cell immunity and attenuates autoimmune responses. Restores immune balance in inflammatory conditions by shifting away from pathological Th1/Th17 dominance.
GHK-Cu
ExperimentalDose
3 mg per day
Frequency
Once daily (morning)
Route
Subcutaneous injection
Mechanism: Supports collagen remodeling and antioxidant defense in fibrotic tissues. Delivers bioavailable copper for enzymatic function and gene expression modulation relevant to tissue repair.
MOTS-c
ExperimentalDose
5 mg twice a week
Frequency
Mondays and Thursdays
Route
Subcutaneous injection
Mechanism: Mitochondrial-derived peptide that enhances mitochondrial function and insulin sensitivity. Activates AMPK signaling to improve metabolic flexibility in metabolic disorders.
KPV
ExperimentalDose
500 mcg per day for 15 days
Frequency
Once daily (morning)
Route
Subcutaneous injection
Mechanism: Potent anti-inflammatory tripeptide that suppresses NF-κB activation and downstream cytokine production. Directly targets the inflammatory cascade driving endometriotic lesion growth.
Methylene Blue
ExperimentalDose
1 mg per day
Frequency
Once daily (morning)
Route
Oral
Mechanism: Alternative electron carrier that bypasses complex I/III bottlenecks in the mitochondrial electron transport chain. Improves cellular energy production and reduces oxidative stress at the mitochondrial level.
Nutritional Support
| Curcumin with Piperine | 1000 mg twice daily oral — inhibits inflammatory pathways and oxidative stress |
| NAC (N-Acetylcysteine) | 1200 mg daily oral — glutathione precursor, antioxidant support |
Critical Dietary Interventions
Environmental controls applied in the study:
- Complete elimination of industrial seed oils (canola, soy, corn, sunflower) — these promote inflammation and estrogenic burden
- Xenoestrogen-free environment — BPA-free containers, filtered water, avoiding plastic food storage and heating
- These dietary and environmental changes remove exogenous triggers that fuel endometriotic lesion growth
Results: Full Protocol vs. Individual Compounds
| Lesion Volume (Week 12) | Control: 120 ± 15 mm³ | Individual: 65 ± 8 mm³ | Full Protocol: 42 ± 5 mm³ |
| Inflammation Score (0-4) | Control: 3.2 ± 0.3 | Individual: 2.0 ± 0.2 | Full Protocol: 1.2 ± 0.2 |
| Pain Threshold | +50% improvement (p<0.001) |
| Cycle Normalization | 85% treated vs. 20% control (p<0.01) |
| HOMA-IR | -50% (p<0.001) |
| Oxidative Stress (ROS/MDA) | -45% / -40% (p<0.001 / p<0.01) |
Track This Protocol
Log doses, monitor interactions, and optimize your stack with AI tools.
Open DoseCraftSource Compounds
Pharma-grade, third-party tested. Our preferred vendor for the DoseCraft community.
Visit Apex PeptidesThis article is for educational and research purposes only. This protocol is based on murine data and has not been validated in human clinical trials. Endometriosis is a serious medical condition requiring professional care. Always consult a licensed healthcare provider, particularly a gynecologist experienced in peptide therapy, before considering any protocol.
Put this research into action
Track your protocol with precision tools. Source pharma-grade compounds from a trusted vendor.
Track in DoseCraft
Build this protocol in 60 seconds. AI-powered dose logging, half-life tracking, and interaction checks.
Open Protocol BuilderGet the Compounds
Pharma-grade, third-party tested peptides from our preferred vendor. Trusted by the community.
Visit Apex PeptidesNot medical advice — educational only. DoseCraft is an information and personal tracking platform. We do not provide medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting any protocol. Affiliate links may be present — we only recommend vendors we trust.